e-learning
resources
Madrid 2019
Monday, 30.09.2019
Lung transplantation: from basic science to clinical outcomes
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of antifibrotic drugs in lung transplantation
J. Carrillo Hernández-Rubio (Majadahonda, Spain), S. Aguado Ibañez (Majadahonda, Spain), R. Laporta Hernández (Majadahonda, Spain), M. Ussetti Gil (Majadahonda, Spain)
Source:
International Congress 2019 – Lung transplantation: from basic science to clinical outcomes
Session:
Lung transplantation: from basic science to clinical outcomes
Session type:
Poster Discussion
Number:
3366
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Carrillo Hernández-Rubio (Majadahonda, Spain), S. Aguado Ibañez (Majadahonda, Spain), R. Laporta Hernández (Majadahonda, Spain), M. Ussetti Gil (Majadahonda, Spain). Impact of antifibrotic drugs in lung transplantation. 3366
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Special issues in elderly people with solitary pulmonary nodule: non intubated thoracic surgery
Transplantation pulmonaire à l’heure de la médecine de précision Lung transplantation in the era of precision medicine
Lung transplantation
Related content which might interest you:
Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018
New antifibrotic drugs: will interstitial diseases patients still need lung transplantation?
Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs
Year: 2020
Evaluation of the biological effects of atorvastatin in lung transplant recipients
Source: Annual Congress 2007 - New insights into clinical lung transplantation
Year: 2007
Immunosuppressive therapy after human lung transplantation
Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=105
Year: 2003
How to use new immunosuppressive drugs in lung transplantation
Source: Annual Congress 2006 - MP5 – How to use new immunosuppressive drugs in lung transplantation
Year: 2006
Lung transplantation for pulmonary hypertension: the impact of new drug therapies
Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria?
Year: 2004
Immunosuppressive therapy after human lung transplantation
Source: Eur Respir J 2004; 23: 159-171
Year: 2004
The influence of different immunosuppressive regimen on non-mnestic cognitive functions in patients after lung transplantation
Source: International Congress 2014 – Maximise lung transplant outcomes: pre- and post-operative issues
Year: 2014
Negative consequences of immunosuppressive therapy on bronchial healing following lung transplantation (LTx)
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013
Update on lung transplantation
Source: Annual Congress 2013 –Ceremony for ERS Research Award on Idiopathic Pulmonary Fibrosis (financially supported by InterMune) followed by Clinical Year in Review I
Year: 2013
Early sirolimus immunosuppression is safe in lung transplantation
Source: Annual Congress 2012 - Optimising outcomes after lung transplantation
Year: 2012
Infectious complications after lung transplantation
Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=193
Year: 2003
The effect of everolimus on lung function and renal status in lung transplanted patients
Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside
Year: 2016
Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
Benefit of pulmonary rehabilitation in candidates for lung transplantation
Source: Annual Congress 2011 - Improving outcomes after lung transplantation
Year: 2011
Airway cellular response to two different immunosuppressive regimens in lung transplant recipients
Source: Eur Respir J 2004; 24: Suppl. 48, 466s
Year: 2004
Anti-inflammatory effects of targeted lung denervation in patients with COPD
Source: Eur Respir J 2015; 46: 1489-1492
Year: 2015
Medical complications of lung transplantation
Source: Eur Respir J 2004; 23: 334-342
Year: 2004
Effects of two immunosuppressive triple therapies on inflammatory cells in lung
Source: International Congress 2014 – Novel approaches in the management of lung transplant candidates and recipients
Year: 2014
Effect of TLI during azithromycin treatment in patients with BOS after lung transplantation
Source: Eur Respir J 2007; 30: Suppl. 51, 174s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept